Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab ACT-AXIS study
Corominas, H.; Alegre, C.; Narvaez, J.; Fernandez-Cid, C. M.; Torrente-Segarra, V.; Rodríguez Gómez, Manuel; Pan, F. M.; Morla, R. M.; Martinez, F. J. R.; Gomez-Centeno, A.; Ares, L. L.; Molina, R. G.; Gonzalez-Albo, S. P.; Dalmau-Carola, J.; Perez-Garcia, C.; Barbazán Alvarez, Ceferino Tomas; Ercole, L.; Terrancle, M. A.
Identifiers
Identifiers
Corporate author
Act-Axis Study GroupDate issued
2019Journal title
MEDICINE
Type of content
Artigo
DeCS
sueño | resultado del tratamiento | estudios prospectivos | factor de necrosis tumoral alfa | mediana edad | depresión | humanos | fatiga | anticuerpos | retratamiento | antirreumáticos | proteína C reactiva | artritisMeSH
Tumor Necrosis Factor-alpha | Sleep | Retreatment | Middle Aged | Humans | Antibodies | Treatment Outcome | Antirheumatic Agents | C-Reactive Protein | Prospective Studies | Depression | Fatigue | ArthritisAbstract
To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 +/- 12.5 years, disease duration 8.7 +/- 7.4 years). Mean change in C-reactive protein level from baseline to week 12 was -11.2 +/- 4.0 (P < .001). Mean Disease Activity Index score (DAS28) decreased from 5.5 +/- 1.0 at baseline to 2.7 +/- 1.3 (P < .001) at week 24. Mean change in Functional Assessment of Chronic Illness Therapy score was -5.4 +/- 11.2 points at week 24. Multiple regression analysis showed that the improvement in DAS28, sleep, and depression explained 56% and 47% of fatigue variance at week 12 and 24, respectively.Tocilizumab is effective in reducing disease activity and results in a clinically significant improvement in fatigue, pain, swollen joint count, morning stiffness, sleepiness, depression, and DAS28; the last 3 were specifically identified as factors explaining fatigue variance with the use of TCZ in RA patients.